Lobe Sciences Ltd.
LOBEF · OTC
8/31/2025 | 8/31/2024 | 8/31/2023 | 8/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.03 | 0.01 | -0.01 |
| FCF Yield | -20.10% | -17.76% | -72.15% | -341.28% |
| EV / EBITDA | -0.34 | -1.00 | -0.58 | 0.03 |
| Quality | ||||
| ROIC | -80.88% | 154.74% | -1,947.10% | -922.84% |
| Gross Margin | 0.00% | 98.71% | 97.14% | 0.00% |
| Cash Conversion Ratio | 0.32 | 0.10 | 0.37 | 0.22 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | – | – | -100.00% |
| Free Cash Flow Growth | -123.01% | 73.10% | 37.06% | 45.79% |
| Safety | ||||
| Net Debt / EBITDA | 1.31 | -0.37 | -0.04 | 0.22 |
| Interest Coverage | -7.00 | -11.34 | -86.93 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 1.41 | 0.00 |
| Cash Conversion Cycle | 0.00 | -162,724.91 | -28,950.90 | 0.00 |